146 related articles for article (PubMed ID: 14565246)
41. Gemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkers.
Li L; Fridley BL; Kalari K; Jenkins G; Batzler A; Weinshilboum RM; Wang L
PLoS One; 2009 Nov; 4(11):e7765. PubMed ID: 19898621
[TBL] [Abstract][Full Text] [Related]
42. Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine.
Heinemann V; Hertel LW; Grindey GB; Plunkett W
Cancer Res; 1988 Jul; 48(14):4024-31. PubMed ID: 3383195
[TBL] [Abstract][Full Text] [Related]
43. Inhibition of topoisomerase I cleavage activity by thiol-reactive compounds: importance of vicinal cysteines 504 and 505.
Montaudon D; Palle K; Rivory LP; Robert J; Douat-Casassus C; Quideau S; Bjornsti MA; Pourquier P
J Biol Chem; 2007 May; 282(19):14403-12. PubMed ID: 17355975
[TBL] [Abstract][Full Text] [Related]
44. Selection of drug-resistant transduced cells with cytosine nucleoside analogs using the human cytidine deaminase gene.
Beauséjour CM; Eliopoulos N; Momparler L; Le NL; Momparler RL
Cancer Gene Ther; 2001 Sep; 8(9):669-76. PubMed ID: 11593336
[TBL] [Abstract][Full Text] [Related]
45. Comparison of antineoplastic activity of 2',2'-difluorodeoxycytidine and cytosine arabinoside against human myeloid and lymphoid leukemic cells.
Bouffard DY; Momparler LF; Momparler RL
Anticancer Drugs; 1991 Feb; 2(1):49-55. PubMed ID: 1958852
[TBL] [Abstract][Full Text] [Related]
46. Metabolism of 4'-thio-beta-D-arabinofuranosylcytosine in CEM cells.
Parker WB; Shaddix SC; Rose LM; Waud WR; Shewach DS; Tiwari KN; Secrist JA
Biochem Pharmacol; 2000 Dec; 60(12):1925-32. PubMed ID: 11108809
[TBL] [Abstract][Full Text] [Related]
47. Apurinic/apyrimidinic endonuclease-1 protein level is associated with the cytotoxicity of L-configuration deoxycytidine analogs (troxacitabine and beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine) but not D-configuration deoxycytidine analogs (gemcitabine and beta-D-arabinofuranosylcytosine).
Lam W; Park SY; Leung CH; Cheng YC
Mol Pharmacol; 2006 May; 69(5):1607-14. PubMed ID: 16481390
[TBL] [Abstract][Full Text] [Related]
48. Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukaemia cell lines.
van Moorsel CJ; Bergman AM; Veerman G; Voorn DA; Ruiz van Haperen VW; Kroep JR; Pinedo HM; Peters GJ
Biochim Biophys Acta; 2000 Mar; 1474(1):5-12. PubMed ID: 10699484
[TBL] [Abstract][Full Text] [Related]
49. Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine.
Muggia F; Diaz I; Peters GJ
Expert Opin Investig Drugs; 2012 Apr; 21(4):403-8. PubMed ID: 22404148
[TBL] [Abstract][Full Text] [Related]
50. Selective targeting of homologous DNA recombination repair by gemcitabine.
Wachters FM; van Putten JW; Maring JG; Zdzienicka MZ; Groen HJ; Kampinga HH
Int J Radiat Oncol Biol Phys; 2003 Oct; 57(2):553-62. PubMed ID: 12957269
[TBL] [Abstract][Full Text] [Related]
51. Kinetic studies on 2',2'-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase.
Bouffard DY; Laliberté J; Momparler RL
Biochem Pharmacol; 1993 May; 45(9):1857-61. PubMed ID: 8494545
[TBL] [Abstract][Full Text] [Related]
52. DNA recombinase activity of eukaryotic DNA topoisomerase I; effects of camptothecin and other inhibitors.
Pommier Y; Jenkins J; Kohlhagen G; Leteurtre F
Mutat Res; 1995 Sep; 337(2):135-45. PubMed ID: 7565862
[TBL] [Abstract][Full Text] [Related]
53. Modulatory activity of 2',2'-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides.
Gandhi V; Plunkett W
Cancer Res; 1990 Jun; 50(12):3675-80. PubMed ID: 2340517
[TBL] [Abstract][Full Text] [Related]
54. Gemcitabine monotherapy in recurrent ovarian cancer: from the bench to the clinic.
Bookman MA
Int J Gynecol Cancer; 2005; 15 Suppl 1():12-7. PubMed ID: 15839953
[TBL] [Abstract][Full Text] [Related]
55. DNA cleavage assay for the identification of topoisomerase I inhibitors.
Dexheimer TS; Pommier Y
Nat Protoc; 2008; 3(11):1736-50. PubMed ID: 18927559
[TBL] [Abstract][Full Text] [Related]
56. Mechanistic studies of the modulation of cleavage activity of topoisomerase I by DNA adducts of mono- and bi-functional PtII complexes.
Malina J; Vrana O; Brabec V
Nucleic Acids Res; 2009 Sep; 37(16):5432-42. PubMed ID: 19589806
[TBL] [Abstract][Full Text] [Related]
57. Quantification of gemcitabine incorporation into human DNA by LC/MS/MS as a surrogate measure for target engagement.
Wickremsinhe ER; Lutzke BS; Jones BR; Schultz GA; Freeman AB; Pratt SE; Bones AM; Ackermann BL
Anal Chem; 2010 Aug; 82(15):6576-83. PubMed ID: 20698580
[TBL] [Abstract][Full Text] [Related]
58. Nucleoside analogues: mechanisms of drug resistance and reversal strategies.
Galmarini CM; Mackey JR; Dumontet C
Leukemia; 2001 Jun; 15(6):875-90. PubMed ID: 11417472
[TBL] [Abstract][Full Text] [Related]
59. Synthesis and restriction enzyme analysis of oligodeoxyribonucleotides containing the anti-cancer drug 2',2'-difluoro-2'-deoxycytidine.
Richardson FC; Richardson KK; Kroin JS; Hertel LW
Nucleic Acids Res; 1992 Apr; 20(7):1763-8. PubMed ID: 1579470
[TBL] [Abstract][Full Text] [Related]
60. Antitumor activity of sugar-modified cytosine nucleosides.
Matsuda A; Sasaki T
Cancer Sci; 2004 Feb; 95(2):105-11. PubMed ID: 14965358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
